These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 10762752)
1. Induction of differentiation by 1alpha-hydroxyvitamin D(5) in T47D human breast cancer cells and its interaction with vitamin D receptors. Lazzaro G; Agadir A; Qing W; Poria M; Mehta RR; Moriarty RM; Das Gupta TK; Zhang XK; Mehta RG Eur J Cancer; 2000 Apr; 36(6):780-6. PubMed ID: 10762752 [TBL] [Abstract][Full Text] [Related]
2. Prevention of preneoplastic mammary lesion development by a novel vitamin D analogue, 1alpha-hydroxyvitamin D5. Mehta RG; Moriarty RM; Mehta RR; Penmasta R; Lazzaro G; Constantinou A; Guo L J Natl Cancer Inst; 1997 Feb; 89(3):212-8. PubMed ID: 9017001 [TBL] [Abstract][Full Text] [Related]
3. Natural metabolites of 1alpha,25-dihydroxyvitamin D(3) retain biologic activity mediated through the vitamin D receptor. Harant H; Spinner D; Reddy GS; Lindley IJ J Cell Biochem; 2000 Apr; 78(1):112-20. PubMed ID: 10797570 [TBL] [Abstract][Full Text] [Related]
4. Novel ring A stereoisomers of 2-methyl-1alpha,25-dihydroxyvitamin D(3) and 2-methyl-20-epi-1alpha,25-dihydroxyvitamin D(3): transactivation of target genes and modulation of differentiation in human promyelocytic leukemia (HL-60) cells. Nakagawa K; Kurobe M; Ozono K; Konno K; Fujishima T; Takayama H; Okano T Biochem Pharmacol; 2000 Mar; 59(6):691-702. PubMed ID: 10677586 [TBL] [Abstract][Full Text] [Related]
5. Resistance of HBL100 human breast epithelial cells to vitamin D action. Agadir A; Lazzaro G; Zheng Y; Zhang XK; Mehta R Carcinogenesis; 1999 Apr; 20(4):577-82. PubMed ID: 10223184 [TBL] [Abstract][Full Text] [Related]
6. The anti-proliferative effects of 1alpha,25(OH)2D3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression. Campbell MJ; Gombart AF; Kwok SH; Park S; Koeffler HP Oncogene; 2000 Oct; 19(44):5091-7. PubMed ID: 11042697 [TBL] [Abstract][Full Text] [Related]
7. 25-Dehydro-1alpha-hydroxyvitamin D3-26,23S-lactone antagonizes the nuclear vitamin D receptor by mediating a unique noncovalent conformational change. Bula CM; Bishop JE; Ishizuka S; Norman AW Mol Endocrinol; 2000 Nov; 14(11):1788-96. PubMed ID: 11075812 [TBL] [Abstract][Full Text] [Related]
8. (23S)- and (23R)-25-dehydro-1alpha-hydroxyvitamin D(3)-26,23-lactone function as antagonists of vitamin D receptor-mediated genomic actions of 1alpha,25-dihydroxyvitamin D(3). Ishizuka S; Miura D; Ozono K; Saito M; Eguchi H; Chokki M; Norman AW Steroids; 2001; 66(3-5):227-37. PubMed ID: 11179730 [TBL] [Abstract][Full Text] [Related]
9. Overexpression of ER and VDR is not sufficient to make ER-negative MDA-MB231 breast cancer cells responsive to 1alpha-hydroxyvitamin D5. Peng X; Jhaveri P; Hussain-Hakimjee EA; Mehta RG Carcinogenesis; 2007 May; 28(5):1000-7. PubMed ID: 17130524 [TBL] [Abstract][Full Text] [Related]
10. Differentiation of human breast carcinoma cells by a novel vitamin D analog: 1alpha-hydroxyvitamin D5. Mehta RR; Bratescu L; Graves JM; Green A; Mehta RG Int J Oncol; 2000 Jan; 16(1):65-73. PubMed ID: 10601550 [TBL] [Abstract][Full Text] [Related]
11. Chemoprevention of mammary carcinogenesis by 1alpha-hydroxyvitamin D5, a synthetic analog of Vitamin D. Mehta RG; Hussain EA; Mehta RR; Das Gupta TK Mutat Res; 2003; 523-524():253-64. PubMed ID: 12628523 [TBL] [Abstract][Full Text] [Related]
12. Regulation of steroid receptor expression by 1alpha-hydroxyvitamin D5 in hormone-responsive breast cancer cells. Hussain-Hakimjee EA; Mehta RG Anticancer Res; 2009 Sep; 29(9):3555-61. PubMed ID: 19667148 [TBL] [Abstract][Full Text] [Related]
13. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer. Chen TC; Schwartz GG; Burnstein KL; Lokeshwar BL; Holick MF Clin Cancer Res; 2000 Mar; 6(3):901-8. PubMed ID: 10741714 [TBL] [Abstract][Full Text] [Related]
14. 25-Hydroxyvitamin D3 1alpha-hydroxylase expression in breast cancer and use of non-1alpha-hydroxylated vitamin D analogue. Segersten U; Holm PK; Björklund P; Hessman O; Nordgren H; Binderup L; Akerström G; Hellman P; Westin G Breast Cancer Res; 2005; 7(6):R980-6. PubMed ID: 16280049 [TBL] [Abstract][Full Text] [Related]
15. The effects of 1alpha,24(S)-dihydroxyvitamin D(2) analog on cancer cell proliferation and cytokine expression. Shany S; Levy Y; Lahav-Cohen M Steroids; 2001; 66(3-5):319-25. PubMed ID: 11179740 [TBL] [Abstract][Full Text] [Related]
16. Evidence that both 1alpha,25-dihydroxyvitamin D3 and 24-hydroxylated D3 enhance human osteoblast differentiation and mineralization. van Driel M; Koedam M; Buurman CJ; Roelse M; Weyts F; Chiba H; Uitterlinden AG; Pols HA; van Leeuwen JP J Cell Biochem; 2006 Oct; 99(3):922-35. PubMed ID: 16741965 [TBL] [Abstract][Full Text] [Related]
17. Identification of VDR-responsive gene signatures in breast cancer cells. Towsend K; Trevino V; Falciani F; Stewart PM; Hewison M; Campbell MJ Oncology; 2006; 71(1-2):111-23. PubMed ID: 17377416 [TBL] [Abstract][Full Text] [Related]
18. Clonal differences in expression of 25-hydroxyvitamin D(3)-1alpha-hydroxylase, of 25-hydroxyvitamin D(3)-24-hydroxylase, and of the vitamin D receptor in human colon carcinoma cells: effects of epidermal growth factor and 1alpha,25-dihydroxyvitamin D(3). Bareis P; Kállay E; Bischof MG; Bises G; Hofer H; Pötzi C; Manhardt T; Bland R; Cross HS Exp Cell Res; 2002 Jun; 276(2):320-7. PubMed ID: 12027461 [TBL] [Abstract][Full Text] [Related]
19. 1alpha,25-dihydroxyvitamin D(3) displays divergent growth effects in both normal and malignant cells. Rashid SF; Mountford JC; Gombart AF; Campbell MJ Steroids; 2001; 66(3-5):433-40. PubMed ID: 11179752 [TBL] [Abstract][Full Text] [Related]
20. Altered nuclear receptor corepressor expression attenuates vitamin D receptor signaling in breast cancer cells. Banwell CM; MacCartney DP; Guy M; Miles AE; Uskokovic MR; Mansi J; Stewart PM; O'Neill LP; Turner BM; Colston KW; Campbell MJ Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2004-13. PubMed ID: 16609009 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]